For BRAF, where the model performed well only in thyroid carcinoma and cutaneous melanoma, balancing the underperforming tumour types improved performance considerably in colorectal and stomach adenocarcinomas (Additional file 1: Figure S8). This evidence concerns the gene BRAF and neoplasm.